MASP-1/C1-INH, ELISA

Investigate and unravel early complement activation in complement-mediated diseases

Complement-mediated inflammation is linked to a wide variety of diseases. In some cases, it is important to intervene as early as possible in this process as it has direct clinical implications. Currently C1-INH administration in its natural or recombinant form is an approved treatment for hereditary angioedema (HAE).

C1-INH or other early complement inhibitors are investigated for better targeted therapies in pending clinical studies. Hence the C1-INH complexes can be used as an indirect marker for ongoing classical or lectin pathway activation.

Why looking at C1-INH and its complexes?

C1-INH administration is an approved common treatment for hereditary angioedema (HAE) and in clinical trials for:

– Covid-19 infections

– Prevention of rejection in kidney transplantation

– Traumatic brain injury and acute ischemic stroke

– Endotoxemia, sepsis, inflammation and multiple organ failure

– Application in end stage renal disease and chronic kidney disease

The key advantages:

– Ready-to-use ELISA’s with a working time of 1 hour and 45 minutes

– Acute and reliable quantification of MASP-1/C1-INH complex

– Uses EDTA-plasma as input sample. No need for complement-preserved serum to assess early lectin pathway activation

– First on the market available ELISA assay to measure early classical and early lectin pathway activation